Your liver clears most drugs with enzymes you partly inherit. One version runs three to five times fast, another barely works, and which you carry is fixed for life. A normal codeine dose in a fast metabolizer becomes morphine faster than the label expects, and breastfed infants of mothers with that variant have died 1.
The list that saves lives is short and settled. Before 5-FU or capecitabine chemo, test DPYD; a 50% starting-dose cut drops first-cycle hospitalization from two-thirds of carriers to a quarter 2. Before 6-mercaptopurine or azathioprine, test TPMT and NUDT15; two bad copies means a tenth of the normal dose or the bone marrow fails 3. Before the HIV drug abacavir, test HLA-B*57:01; screening erased the severe reaction 4. Before carbamazepine in an East or Southeast Asian patient, test HLA-B*15:02 for the risk of skin peeling off like a burn.
The list everyone actually buys is the contested one. Antidepressant panels are marketed hard, but the payoff is a modest lift after a first drug fails, not a transformation 5. Testing CYP2C19 after a heart stent has a clearer three-month benefit 6. In older patients on many drugs, a twelve-gene panel cut serious adverse reactions by a third 7.
You don't buy this off a shelf. You ask for the right gene at the right moment.
Cost and coverage. Self-pay runs $300 to $500. Medicare covers it at no cost when a listed drug-gene pair is in play, Medicaid generally covers it, and private insurers vary widely. Ask the lab to send the result into your doctor's electronic record; a paper report in a drawer helps no one.
What you get. In one of the four high-stakes moments the payoff is immediate: the dose or the drug changes and a near-fatal first-cycle event doesn't happen. In the contested middle, a stent or a second antidepressant, it is real but modest. Everywhere else it is a card in your record that sits unused, until one day a doctor reaches for the wrong prescription and it isn't.
The fine print โ when to skip it, and what people get wrong
Tested but no benefit: the next prescriber never sees the result; the panel skipped the variants for your ancestry (older ones miss the warfarin variants that drive dosing in African American patients) 8; or a drug you take (paroxetine, fluoxetine) blocks the enzyme, so a normal genotype acts poor.
It is not "the personalised medicine test"; most drugs you'll take have no relevant gene pair. It does not tell you which antidepressant will work, only which are cleared abnormally fast or slow. The pharmacogenetic report in a consumer ancestry kit is narrow and warns against changing drugs without a clinician.
- 1FDA (2017). FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children. link
- 2Amstutz U, et al. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology & Therapeutics. link
- 3Relling MV, et al. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clinical Pharmacology & Therapeutics. link
- 4Mallal S, et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine. link
- 5Oslin DW, et al. (2022). Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. link
- 6Pereira NL, et al. (2020). Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. link
- 7Swen JJ, et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet. link
- 8Kimmel SE, et al. (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. New England Journal of Medicine. link
Related in the handbook (10)
- โ Genes are one driver of how a drug lands; for a few medications the manufacturer is another.
- โ Caffeine clearance is a familiar example of the metaboliser variation pharmacogenomics looks at.
- โ CYP1A2 decides whether coffee protects your heart or strains it. One of the cleaner real-world uses of the test.
- โ Interactions and inherited metabolism both bend how a drug hits you โ the gene test explains the part diet and supplements can't.
- โ G6PD status is a pharmacogenetic fact: it tells doctors which drugs and foods can trigger a crisis.
- โ One useful, concrete branch of genetic testing is reading the genes that decide how you handle certain drugs.
- โ Genes set how fast you clear a drug; this is the food-and-herb version of the same metabolism story.
- โ This single-gene check before an HIV drug is the flagship example of pharmacogenomic testing in practice.
- โ Unlike the validated drug-gene matches, an MTHFR result almost never changes treatment โ a useful contrast to keep straight.
- โ A pharmacogenomic result is a card for your records โ put it on the health summary you bring to any prescriber.
Pharmacogenomic Testing
A cheek swab. Results in a week. The harder part is getting a doctor to order it and to actually use the result later.
$300โ$500 out of pocket if you self-pay; often free with Medicare, Medicaid, or after a clinician documents you need it. One-time.
Rock-solid for a small list of drugs that can kill you at standard doses. Mixed for the broader pitch of "test once, personalise everything."
One genetic test, once. For the meds it covers, it cuts your odds of a bad drug reaction by about a third.
For a short list of high-stakes drugs โ certain chemo agents, codeine, some epilepsy meds โ testing first prevents deaths that standard prescribing causes.
If you've tried an antidepressant and it didn't work or made you sick, the test can flag a gene-drug mismatch and shorten the search for one that fits.